

Grow with Ginkgo

Q2 2026 Update & Business Review

August 5, 2026



Disclaimer

FORWARD-LOOKING STATEMENTS

This presentation, the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adaptations to meet our customers' needs and the integration of our autonomous lab platform with third-party artificial intelligence models, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, including the timing for attaining Adjusted EBITDA breakeven, potential customer success, including successful application of our offerings by our customers, expected benefits from our strategic partnerships and collaborations (including with named partners such as ProQR and Amazon), the anticipated growth, scaling, capacity, capabilities and competitive position of our autonomous lab (including Nebula) and of our Cloud Lab, Datapoints and Solutions offerings, including our increase of the total number of devices housed in Nebula's RACs and other expected features such as the automated nano-scale chemistry on RACs, multistep synthesis, safety-seq and biochemical screens, our beliefs and estimates regarding the size, composition, growth and pace of adoption of the market for autonomous laboratory and related services (including the displacement of manual laboratory work), expectations concerning increased government investment in and contracting for autonomous laboratory infrastructure, expectations regarding the development, performance and future enhancements of our platform and new product and service introductions, and expectations with regard to revenue, including our ability to meet all milestones and achieve the maximum revenue available under certain of our customer arrangements, expenses, our full year 2026 outlook including the total cash burn guidance, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," "target," "goal," "aim," "design," "forecast," "outlook," "guidance," "seek," "position," and similar expressions, as well as the negatives of such terms. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our platform programs and assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith, (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies, including potential adverse effects from the U.S. government shutdown, (xiv) our ability to scale, expand the capacity of, and continue to develop the capabilities of our autonomous lab (including Nebula) on the timelines and to the extent we anticipate, (xv) the pace and degree to which autonomous laboratory infrastructure is adopted by, and displaces manual laboratory work in, the broader life sciences and industrial biotechnology markets, (xvi) the actual size, composition and growth of the addressable markets we target, which may differ materially from our estimates, (xvii) our ability to integrate our autonomous lab platform with third-party artificial intelligence models and other technologies, and the rate of development and adoption of such technologies, and (xviii) our ability to maintain and expand strategic partnerships and customer relationships, including those with named partners referenced in this release. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 26, 2026 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

INDUSTRY AND MARKET DATA

In this presentation, Ginkgo relies on and refers to certain information and statistics regarding the markets and industries in which Ginkgo competes. Such information and statistics are based on Ginkgo management's estimates and/or obtained from third-party sources, including reports by market research firms and company filings. While Ginkgo believes such third-party information is reliable, there can be no assurance as to the accuracy or completeness of the indicated information, and Ginkgo has not independently verified the accuracy or completeness of the information provided by the third-party sources.

USE OF NON-GAAP FINANCIAL MEASURES

Certain of the financial measures included in this presentation, including Adjusted EBITDA, cash flow and cash burn, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation included in this presentation for additional information regarding certain of the non-GAAP financial measures included in this presentation, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures. Ginkgo does not reconcile its forward-looking non-GAAP financial measures to the corresponding GAAP measures, due to variability and difficulty in making accurate forecasts and projections and/or certain information not being ascertainable or accessible; and because not all of the information, such as unrealized equity gains and losses necessary for a quantitative reconciliation of these forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measure, can be predicted with reasonable accuracy and is available to Ginkgo without unreasonable efforts. For the same reasons, Ginkgo is unable to address the probable significance of the unavailable information. Ginkgo provides non-GAAP financial measures that it believes will be achieved, however it cannot accurately predict all of the components of the adjusted calculations and the GAAP measures may be materially different than the non-GAAP measures.

TRADEMARKS

This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners, and Ginkgo's use thereof does not imply an affiliation with, or endorsement by, the owners of such trademarks, service marks, trade names and copyrights. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, © or ® symbols, but Ginkgo will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights.



Agenda

Introduction

Jason Kelly, Co-Founder and CEO

Q2 2026 Financial Update

Steve Coen, CFO

Strategic Review

Jason Kelly, Co-Founder and CEO

Q&A Session

*Moderated by Daniel Marshall, Sr. Manager of
Communications and Ownership*



OUR MISSION


Make biology easier to engineer

IN 2026 GINKGO WILL FOCUS AND INVEST TO WIN AUTONOMOUS LABS

Focus Ginkgo's efforts on Autonomous Labs as the common platform for biotechnology research. Invest to extend our current progress in technology.


Demonstrate the capabilities of Autonomous Labs by decommissioning the majority of Ginkgo's lab benches, walk-up automation, and workcells and moving our three R&D services businesses onto a single, large Autonomous Lab.

Book new sales of Autonomous Labs in biopharma, national labs, and research universities.



Our improved cash burn allows us to invest in winning Autonomous Labs (Unaudited)

ANNUAL CASH BURN⁽¹⁾ (\$M)



\$302M

Ginkgo remains in a strong financial position with \$302 million in cash, cash equivalents, and marketable securities with no bank debt as of Q2 2026

+\$87M

Ginkgo has also set aside \$87 million in restricted cash for customers and operating activities

(1) References to cash burn is defined as change in GAAP cash, cash equivalents, and marketable securities excluding Company imposed cash restrictions, as adjusted for unrealized equity gains and losses. Cash burn excludes net proceeds from ATM sales. For a reconciliation of Cash burn, see the Appendix.



Agenda

Introduction

Jason Kelly, Co-Founder and CEO

Q2 2026 Financial Update

Steve Coen, CFO

Strategic Review

Jason Kelly, Co-Founder and CEO

Q&A Session

*Moderated by Daniel Marshall, Sr. Manager of
Communications and Ownership*



Q2 2026 Financial Summary (Unaudited)

In millions of USD	Three Months Ended June 30,			Six Months Ended June 30,		
	2026	2025	% YoY	2026	2025	% YoY
Revenue ⁽¹⁾	\$20	\$39	(48%)	\$40	\$77	(49%)
Costs and operating expenses:						
Cost of other revenue ⁽²⁾	1	4	(62%)	4	7	(41%)
Research and development ⁽²⁾	30	31	(4%)	60	80	(25%)
General and administrative ⁽²⁾	12	16	(26%)	24	36	(31%)
Stock-based compensation ⁽³⁾	8	19	(58%)	25	36	(32%)
Depreciation and amortization	12	15	(19%)	25	30	(16%)
Restructuring charges ⁽⁴⁾	0	4	(100%)	0	8	(100%)
Carrying cost of excess space (net of sublease income) ⁽⁵⁾	14	12	15%	30	24	25%
Merger and acquisition related expense (income) ⁽⁶⁾	1	(4)	(131%)	1	(5)	(124%)
Other (income) expense, net ⁽⁷⁾	(1)	(5)	(71%)	3	(2)	(240%)
Income taxes	0	(0)	(145%)	0	\$0	(125%)
Net loss from continuing operations	(57)	(54)	(7%)	(133)	(137)	2%
Total Adjusted EBITDA ⁽⁸⁾	(36)	(25)	(44%)	(79)	(70)	(13%)
Capital expenditures (net of tenant improvement allowance)	3	0	100%	5	4	25%
Cash burn ⁽⁹⁾	(45)	(27)	67%	(93)	(96)	(3%)

1. Six months ended June 30, 2025 includes \$7.5 million of non-cash revenue from a release of deferred revenue relating to the mutual termination of a customer agreement with BiomEdit.
2. The costs and operating expenses exclude expenses which are separately captioned below.
3. Includes \$0.4 million and \$0.2 million in employer payroll taxes for the three months ended June 30, 2026 and 2025, respectively, and \$1.3 million and \$0.5 million for six months ended June 30, 2026 and 2025, respectively.
4. Restructuring charges primarily consist of employee termination costs from the reduction-in-force commenced in June 2024 and substantially concluded by December 31, 2025.
5. The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.
6. Represents transaction and integration costs directly related to mergers, acquisitions and divestitures, including: (i) legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses, (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions, and (iv) securities litigation costs.
7. Includes interest income, interest expense, loss on investments, changes in fair value of certain assets and liabilities, and other gains and losses.
8. For a reconciliation of Adjusted EBITDA, see the Appendix.
9. References to cash burn is defined as change in GAAP cash, cash equivalents, and marketable securities excluding Company imposed cash restrictions, as adjusted for unrealized equity gains and losses. Cash burn excludes net proceeds from ATM sales. For a reconciliation of Cash burn, see the Appendix.

Ginkgo reaffirms total cash burn guidance

<i>In millions of USD</i>	Historical	Outlook
	<u>FY2025</u>	<u>FY2026</u>
Total cash burn ⁽¹⁾	(\$171)	(\$150) - (\$125)

(1) References to cash burn is defined as change in GAAP cash, cash equivalents, and marketable securities excluding Company imposed cash restrictions, as adjusted for unrealized equity gains and losses. Cash burn excludes net proceeds from ATM sales. For a reconciliation of historical Cash burn, see the Appendix.



Agenda

Introduction

Jason Kelly, Co-Founder and CEO

Q2 2026 Financial Update

Steve Coen, CFO


Strategic Review

Jason Kelly, Co-Founder and CEO

Q&A Session

*Moderated by Daniel Marshall, Sr. Manager of
Communications and Ownership*



A large, modern laboratory setting with multiple rows of automated liquid handling workstations. Each workstation consists of a white base unit on wheels and a clear safety enclosure. On top of each enclosure is a multi-well plate handler. The brand name 'WhisperFlow' is visible on the top of the units. The background shows more equipment and laboratory shelving.

OUR MISSION

**Make biology
easier to engineer**

We believe...

1

Autonomous labs are becoming an imperative for American science.

2

Nebula, our autonomous lab, is the largest in the world—and it is scaling rapidly.

3

We are using the autonomous lab to compete with offshore CROs.

We believe...

1

Autonomous labs are becoming an imperative for American science.

2

Nebula, our autonomous lab, is the largest in the world—and it is scaling rapidly.

3

We are using the autonomous lab to compete with offshore CROs.

The frontier of US biotechnology is being offshored to China

THE WALL STREET JOURNAL.

HEALTH • PHARMA

Big Pharma Is Turning to China for the Newest Drug Ideas

China's biotechs are faster and have lower costs, and its drug research threatens to soon overtake the West's

S+ | SPECIAL REPORT

The China question is tearing biotech apart

Its ascent is forcing U.S. firms and investors to pick a side: Is the country an ally or an existential threat?

← r/biotech • 4d ago
Rare_Stand_9447

Working in China

Open Discussion

I'm an extremely frustrated bench scientist having no luck finding work 6 months after a layoff, despite living in a "hub" (San Francisco). I've been striking up a lot of LinkedIn conversations with near-strangers, though, and while none of it has generated any job leads, I did get an interesting suggestion. One biopharma startup CEO told me that he doesn't hire for any bench work in the States, and outsources it all to China. He said, "Have you considered working in China?" I'm not Chinese or even Chinese-American. Is looking for work in China a completely crazy idea? If it is, in fact, a reasonable idea, how would I even go about doing that, considering the fact that I only speak English?

...



Jason Kelly, the co-founder and CEO of Ginkgo Bioworks, poses with rows of reconfigurable automation carts in Ginkgo's automated lab in Boston. Sophie Park for STAT

The US must automate lab work to remain globally competitive in science

Trump Administration Announces More Than \$5 Billion for the Genesis Mission, a National Mission on AI for Science

NSF announces \$400M investment in new national network of AI-programmable cloud laboratories in alignment with the U.S. government's Genesis Mission

July 22, 2026

Accelerate Autonomous Experimentation: Closed-loop autonomous laboratories can collapse discovery timelines by orders of magnitude and enable science at a truly industrial scale. Focus investments in robotics and automated laboratories, leveraging industry demand and federal R&D to ensure our scientific equipment industrial base is built on the world's best hardware and software and leads the charge in the coming scientific revolution.

SCIENCE A NEW GOLDEN AGE



A REPORT TO THE PRESIDENT

BY

MICHAEL KRATSIOS
DIRECTOR OF THE WHITE HOUSE OFFICE
OF SCIENCE AND TECHNOLOGY POLICY

JULY 2026



Ginkgo is building the first autonomous lab for a national lab under the Genesis Mission.



Ginkgo building Autonomous Labs for MIT, Caltech, Maryland and Northwestern

UMD Selected for \$17.3M NSF Award to Establish Autonomous Biomanufacturing Laboratory



Post

MIT Media Lab Awarded \$1M Grant to Launch First Cloud Laboratory for Learning

A new platform will let anyone with a computer conduct real lab experiments at the intersection of biology, AI, and robotics.



**Amount of
Automation**



**Request
Flexibility**

**Amount of
Automation**



Autonomous Car




**Request
Flexibility**

**Amount of
Automation**




Autonomous Car



**Request
Flexibility**

**Amount of
Automation**




Traditional
Automation
Workcell



**Request
Flexibility**



**Amount of
Automation**



Traditional
Automation
Workcell




**95%+ of
research budget!**

**Request
Flexibility**



**Amount of
Automation**



The ROI for an autonomous lab is clear.

Our manual lab used **~3x the space per instrument** compared to our autonomous lab.

Traditional Lab



Operational 40 hours a week.

Autonomous Lab



Operational 168 hours a week
(a 4x improvement).

Repeatability, traceability, and electronic records of all operations are essential for AI-driven scientific work and are greatly enabled by robotic labs.



Autonomous labs increase the number of jobs for US scientists by increasing the return on investment of their knowledge



150 Extra Engineers

An IBM Electronic Calculator speeds through thousands of intricate computations so quickly that on many complex problems it's like having 150 EXTRA Engineers.

No longer must valuable engineering personnel . . . now in critical shortage . . . spend priceless creative time at routine repetitive figuring.

Thousands of IBM Electronic Business Machines . . . vital to our nation's defense . . . are at work for science, industry, and the armed forces, in laboratories, factories, and offices, helping to meet urgent demands for greater production.

 **IBM** INTERNATIONAL BUSINESS MACHINES



We believe...

1

Autonomous labs are becoming an imperative for American science.

2

Nebula, our autonomous lab, is the largest in the world—and it is scaling rapidly.

3

We are using the autonomous lab to compete with offshore CROs.


**Ginkgo has the
largest
autonomous lab
in the world.**






Nebula now has 105 RACs and has the capacity to run experiments for dozens of our scientists at once every day and night.






100+ protocols (30+ unique) submitted by scientists in a single day running across 100+ lab devices on an integrated automation setup.

We believe there is nothing else like Nebula in the world today. It is proof that autonomous labs are feasible.



24/7 lab operations
for variable lab work





hiphopscienceshow

Original audio

labskillsacademy

Original audio



itsalexml and 2 others


barbz_ro0m • Original audio



mellythesciencegeek

Original audio

Nebula tours are becoming a trend.



gabastorga and 4 others

Glass Animals • Take A Slice




the_brain_scientist

Boston, Massachusetts

Come visit!!!

<https://calendly.com/ginkgo-bio/tour-ginkgo>





Try your protocols on Nebula



We believe...

1

Autonomous labs are becoming an imperative for American science.

2

Nebula, our autonomous lab, is the largest in the world—and it is scaling rapidly.

3

We are using the autonomous lab to compete with offshore CROs.

Onshoring American Industry Through Technology



SendCutSend raises \$110M with backing from Sequoia

US on-demand metal parts manufacturer SendCutSend has raised \$110 million in new funding in a deal led by Sequoia Capital and Paradigm, alongside Stripe's founders, boosting its valuation...

Fast custom parts, at any scale

Sheet metal fabrication, CNC machining, and much more delivered in as little as 24 hours.

[GET STARTED](#)

Whatever you're building we've got you. No CAD? Start with a [template!](#)



Reshoring U.S. R&D with critical infrastructure

Ginkgo's goal is for its autonomous labs to outpace China's R&D labor efficiencies


“China has achieved a meaningful increase in speed and reduced levelized cost of biopharma R&D ... Faster development and stronger ecosystem economics materially lower biopharma R&D costs

— McKinsey Global Institute, 2026

THE IMPLICATION

1 U.S. autonomous labs are required to beat the efficiencies delivered by China's low labor costs.


2 Ginkgo's innovative pharma services continue to onshore American industry through innovation..





Ginkgo Datapoints ADME Services: ~10x cheaper than WuXi. 17 customers in first 6 weeks.

Absorption, **Distribution**, Metabolism, Excretion



Same assays trusted industry wide. Automated.

\$199

per compound

ADME-One — 5 assays + PK projection + compound management

w/ partners Inductive Bio and Tangible Scientific

\$2,000–5,000+

per compound

Traditional Western ADME vendors — panel only

\$1,000–2,500+

per compound

Chinese CRO vendors — panel only

Data panel shows comparison for plasma protein binding versus published data from well-known global CRO, $r=0.97$



Validating Ginkgo Datapoints' Tier 1 ADME Assay

Internal Assay Quality Control
CVs: Average < 15%
Replicate Variability: Spearman Coefficient ≥0.9

External Agreement
Selected control compounds compared to publicly available data in literature and from industry peers
Binning Agreement: ~80% of compound fall into correct bins
Ranking: Spearman Coefficient ≥0.7

Objective


Demonstrate that Datapoints' ADME services produce *high quality and reproducible data* which meet reasonable expectations for agreement with external CROs.

Provide customers with the *data they need to trust Ginkgo* as a reliable ADME service provider.



Kinetic Solubility


Rank Agreement: Strong rank order between Ginkgo and industry peer



Spearman's Rho
0.97

Binning Agreement: Ginkgo bins compounds very similarly to industry peer

Compound	Industry Peer	Ginkgo Bin
Amiodarone	Low	Low
Cinnarizine	Low	Low
Flunarizine	Low	Low
Nicardipine	Low	Low
Tamoxifen	Low	Low
Haloperidol	Mid	Mid
Griseofulvin	Mid	Mid
Phenytoin	Mid	Mid




Bins: Low <10 uM; Medium = 10–100 uM; High = >100 uM



MDCK-MDR1 Permeability


Rank Agreement: Strong rank order between Ginkgo and industry peer



Spearman's Rho
0.81

Binning Agreement: Ginkgo bins compounds very similarly to industry peer

Compound	Industry Bin	Ginkgo Bin
Cimetidine	Low	Mid
Atenolol	Low	Mid
Nicardipine	-	Mid
Prazosin	-	Mid
Quinidine	Mid	Mid
Fluconazole	Mid	Mid
Metoprolol	-	High
Warfarin	High	High
Verapamil	-	High
Carbamazepine	High	High
Propranolol	High	High
Acetaminophen	High	High
Caffeine	-	High




$P_{app(A-B)}$ Bins: Low = $<1 \times 10^{-6}$ cm/s, Medium = $1-10 \times 10^{-6}$ cm/s, High = $>10 \times 10^{-6}$ cm/s



Microsomal Stability (human microsomes)

Rank Agreement: Strong rank order between Ginkgo and industry peer


Binning Agreement: Ginkgo bins compounds very similarly to industry peer



Spearman's Rho
0.93

Compound	Industry Peer	Ginkgo
Carbamazepine	Low	Mid
Metoprolol	Mid	Mid
Fluoxetine	Mid	Mid
Erythromycin	High	High
Propranolol	High	High
Omeprazole	High	High
Diclofenac	High	High
Verapamil	High	High
Midazolam	High	High

Average Intrinsic Clearance per Compound (uL/min/mg)




Bins: Low < 6.7 uL/min/mg; Medium = 6.7 -15.6 uL/min/mg; High = >15.6 uL/min/mg



P450 Inhibition (3A4M)



Rank Agreement: Strong rank order between Ginkgo and industry peer



Spearman's Rho
0.86

Binning Agreement: Ginkgo bins compounds very similarly to industry peer

Compound	Industry Peer Bin	Ginkgo Bin
Ketoconazole	Low	Low
Disulfiram	Low	Low
Fluoxetine	High	High
Mibefradil	Low	Low
Paroxetine	High	High
Ritonavir	Low	Low
Voriconazole	Medium	High
Atipamezole	Low	Medium




Bins: Low < 1 uM; Medium = 1–10 uM; High = >10 uM




Plasma Protein Binding

Rank Agreement: Strong rank order between Ginkgo and industry peer



Spearman's Rho
0.97

Value Agreement: Ginkgo returns data that correlates strongly with values from literature and an industry peer



P value	r^2
<0.01	0.93

Compound	Fraction unbound - (literature / Industry Peer)	Fraction unbound - Ginkgo
Diclofenac	0.005	< LOD
Telmisartan	0.005	0.03
Warfarin	0.008	0.003
Montelukast	0.01	0.013
Piroxicam	0.015	0.042
Tolbutamide	0.04	0.055
Fluoxetine	0.06	0.055
Sulindac	0.06	0.07
Verapamil	0.094	0.14
Imipramine	0.11	0.15
Propranolol	0.24	0.23
Diltiazem	0.28	0.18
Cimetidine	0.8	1.2
Fluconazole	0.94	0.91



Case Study: 320 Compounds from the LOPAC library run on 3 Tier 1 ADME assays

Assays	Kinetic solubility Microsomal stability P450 inhibition
Data Package	Raw data, metadata, and summary QC metrics (CV%, Robust Z') for 320 compounds selected from LOPAC and controls
Experimental Design	Solubility tested in PBS pH7.4, static incubation for 2 hours at 37°C Human liver microsomes incubated at t=0, 10, 20, 30, 45 minutes CYP2D6 tested at 7 non-zero concentrations
Key Results	Controls comparable to literature values 100% process QC for each assay
Link	DOWNLOAD OUR DATASETS https://datapoints.ginkgo.bio/dataset-access

*Doran, et al., 2022 – Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting Approach
U.S. FDA – Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers; Wang, J., Miniaturized and High-Throughput Metabolic Stability Assay Enabled by the Echo® Liquid Handler.



[GDPsm1.1]: Tier 1 ADME data drop



SmolDev

Kinetic solubility

Microsomal stability

P450 inhibition

MDCK permeability


Plasma Binding PPB

[DOWNLOAD OUR DATASETS](#)

Compound counts by Solubility & MW

High	3	12	3
Medium	25	37	9
Low	70	70	15
	Small	Medium	Large

Histogram of Compound Solubility



[Summary Statistics] - Diversity of compounds with range of solubilities

3rd Party Case Study

The platform is technically clean.

Spearman $\rho = 0.977$ on solubility replicates; $\rho = 0.975$ on log IC50 replicates; $\rho = 0.678$ ($p = 4 \times 10^{-5}$) vs literature HLM Cl_{int}
77% within 2-fold and Bland–Altman bias of $-0.07 \log_{10}$.

All in-assay controls passed published bands.

inflexa



[Expected Soon] - Call us to beta test

Chemical Synthesis on Nebula

Synthesis

Plate Based Chemistry



Synthesis in well plates designed to enable robotic execution of the most commonly used medicinal chemistry reactions on liquid handlers.

Purification


Crude → DMSO stock



Analytical scale purification (currently enabled for natural product workflows). System build ongoing in BW4.

Inert Atmosphere

MBraun Glove Box



Inert atmosphere RACs enabled for PNNL microbial applications. Now want to demonstrate use for a broader chemistry scope.

Chemistry is a natural complement to the biological assays we've developed at Ginkgo

Small molecules account for 65% of drug approvals, but still require significant triaging and optimization.

TRADITIONAL
Manual, serial synthesis




AUTOMATE



WITH GINKGO AUTOMATION
Automated, parallel synthesis



INTEGRATE



FEEDBACK

FEEDS INTO
Downstream biology




**Adaptive chemistry informed by
real-time biological feedback**

ADME · In vitro Tox · Functional Assays

**Automation doesn't just lower costs, it unlocks entirely new ways to run more productive R&D.
Automated chemistry feeds automated biology → bona fide lab-in-the-loop discovery.**





<https://datapoints.ginkgo.bio/>

A wide-angle photograph of a modern, brightly lit laboratory. Several scientists in white lab coats and safety glasses are working. In the foreground, a large piece of automated equipment with a glass enclosure is visible. In the background, more lab equipment, including a machine labeled 'WhisperFlow', and a digital display showing data are visible. The overall atmosphere is one of high-tech scientific research.

**Buy an
autonomous lab or
try our lab services.**





**Let's grow the world
we want to see**

jason@ginkgobioworks.com

Agenda

Introduction

Jason Kelly, Co-Founder and CEO

Q2 2026 Financial Update

Steve Coen, CFO

Strategic Review


Jason Kelly, Co-Founder and CEO

Q&A Session

*Moderated by Daniel Marshall, Sr. Manager of
Communications and Ownership*



APPENDIX



Adjusted EBITDA Reconciliation (Unaudited)

<i>In millions of USD</i>	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Net loss from continuing operations ⁽¹⁾	\$ (57.3)	\$ (53.2)	\$ (133.4)	\$ (136.5)
Interest income, net	(3.2)	(6.1)	(6.8)	(12.2)
Income tax (benefit) expense	0.1	(0.3)	0.0	(0.2)
Depreciation and amortization	12.3	15.2	25.1	30.1
EBITDA	\$ (48.1)	\$ (44.3)	\$ (115.0)	\$ (118.8)
Stock-based compensation ⁽²⁾	8.0	18.8	24.7	36.5
Restructuring charges ⁽³⁾	0.0	3.6	0.0	8.0
Merger and acquisition related expenses ⁽⁴⁾	1.1	(3.6)	1.1	(4.5)
Loss (gain) on investments	(2.0)	0.2	(0.8)	3.9
Loss on equity method investment	4.7	0.0	4.7	0.0
Change in fair value of notes receivable	0.0	0.0	6.8	5.3
Adjusted EBITDA	\$ (36.3)	\$ (25.4)	\$ (78.5)	\$ (69.6)

1) All periods include non-cash revenue when earned, including \$7.5 million recognized in the six months ended June 30, 2025, recognized pursuant to the termination of revenue contracts with Biomedit.

2) Includes \$0.4 million and \$0.2 million in employer payroll taxes for the three months ended June 30, 2026 and 2025, respectively. Includes \$1.3 million and \$0.5 million in employer payroll taxes for the six months ended June 30, 2026 and 2025, respectively

3) Restructuring charges primarily consist of employee termination costs from the reduction-in-force commenced in June 2024 and substantially concluded by December 31, 2025.

4) Represents transaction and integration costs directly related to mergers, acquisitions and divestitures, including: (i) legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses, (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions, and (iv) securities litigation costs. Not included in this adjustment are acquired in-process research and development expenses, which totaled zero for both the three months and six months ended June 30, 2026 and 2025, respectively.

Cash Burn Reconciliation (unaudited)

In millions of USD	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Net decrease in cash, cash equivalents and restricted cash	\$ (17)	\$ (105)	\$ (40)	\$ (354)
Net increase (decrease) in marketable securities	(14)	66	(39)	255
Net proceeds from ATM	(17)	0	(17)	0
Other adjustments	2	2	3	3
Cash Burn ⁽¹⁾	\$ (45)	\$ (38)	\$ (93)	\$ (96)

(1) Cash burn is defined as change in GAAP cash, cash equivalents, and marketable securities excluding Company imposed cash restrictions, as adjusted for unrealized equity gains and losses. Cash burn excludes net proceeds from ATM sales.



Cash Burn Reconciliation (unaudited)

<i>In millions of USD</i>	Twelve Months Ended December 31,	
	2025	2024
Net decrease in cash, cash equivalents and restricted cash	\$ (393)	\$ (383)
Net increase (decrease) in marketable securities	235	0
Net proceeds from ATM	(19)	0
Restricted stock movements	6	0
Cash Burn ⁽¹⁾	\$ (171)	\$ (383)

(1) Cash burn is defined as change in GAAP cash, cash equivalents, and marketable securities excluding Company imposed cash restrictions, as adjusted for unrealized equity gains and losses. Cash burn excludes net proceeds from ATM sales.